# Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

> **NCT07644312** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 12 (estimated)

## Conditions studied

- High Grade Glioma
- Diffuse Intrinsic Pontine Glioma
- WHO Grade 3 Glioma
- WHO Grade 4 Glioma
- Replication Repair Deficient

## Interventions

- **DRUG:** Opdualag

## Key facts

- **NCT ID:** NCT07644312
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-03-01
- **Primary completion:** 2033-03-01
- **Final completion:** 2038-03-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644312, "Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*